Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more
Mayne Pharma Group Limited (MAYNF) - Total Liabilities
Latest total liabilities as of June 2025: $644.32 Million USD
Based on the latest financial reports, Mayne Pharma Group Limited (MAYNF) has total liabilities worth $644.32 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mayne Pharma Group Limited - Total Liabilities Trend (2007–2025)
This chart illustrates how Mayne Pharma Group Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mayne Pharma Group Limited Competitors by Total Liabilities
The table below lists competitors of Mayne Pharma Group Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hefei Department Store Group Co Ltd
SHE:000417
|
China | CN¥6.62 Billion |
|
Monogram Orthopaedics Inc. Common Stock
NASDAQ:MGRM
|
USA | $6.38 Million |
|
Bonava AB (publ)
ST:BONAV-B
|
Sweden | Skr8.70 Billion |
|
Seven West Media Limited
PINK:WANHY
|
USA | $1.15 Billion |
|
Guangdong PAK Corporation Co Ltd
SHE:300625
|
China | CN¥896.13 Million |
|
Bonava AB B
LSE:0RHA
|
UK | Skr15.39 Billion |
|
Binh Dinh Pharmaceutical and Medical Equipment JSC
VN:DBD
|
Vietnam | ₫862.89 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Mayne Pharma Group Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mayne Pharma Group Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mayne Pharma Group Limited (2007–2025)
The table below shows the annual total liabilities of Mayne Pharma Group Limited from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $644.32 Million | -6.48% |
| 2024-06-30 | $688.99 Million | +12.25% |
| 2023-06-30 | $613.77 Million | -16.01% |
| 2022-06-30 | $730.81 Million | +5.67% |
| 2021-06-30 | $691.61 Million | -11.66% |
| 2020-06-30 | $782.87 Million | +25.81% |
| 2019-06-30 | $622.26 Million | +4.52% |
| 2018-06-30 | $595.35 Million | -1.19% |
| 2017-06-30 | $602.50 Million | -48.99% |
| 2016-06-30 | $1.18 Billion | +471.32% |
| 2015-06-30 | $206.74 Million | +94.04% |
| 2014-06-30 | $106.55 Million | -5.29% |
| 2013-06-30 | $112.50 Million | +382.16% |
| 2012-06-30 | $23.33 Million | -20.91% |
| 2011-06-30 | $29.50 Million | -35.30% |
| 2010-06-30 | $45.60 Million | +13654.27% |
| 2009-06-30 | $331.53K | +30.09% |
| 2008-06-30 | $254.85K | -74.42% |
| 2007-06-30 | $996.16K | -- |